Preventing heart failure admissions with sodium-glucose cotransporter-2 inhibitors versus angiotensin receptor-neprilysin inhibitors: A target trial emulation study

被引：0

作者：

Jeong, Han Eol ^{[1
]}

Park, Sohee ^{[2
]}

Bea, Sungho ^{[3
]}

Noh, Yunha ^{[4
]}

Lip, Gregory Y. H. ^{[5
,6
]}

You, Seng Chan ^{[7
]}

Choi, Eue-Keun ^{[8
]}

Shin, Ju-Young ^{[3
]}

机构：

[1] Sungkyunkwan Univ, Seoul, South Korea

[2] UCL, Sch Pharm, London, England

[3] Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea

[4] McGill Univ, Montreal, PQ, Canada

[5] Univ Liverpool, Liverpool, Merseyside, England

[6] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England

[7] Yonsei Univ, Coll Med, Seoul, South Korea

[8] Seoul Natl Univ, Coll Med, Seoul, South Korea

来源：

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

662

引用

页码：311 / 311

页数：1

共 50 条

[41] Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Racial Differences and a Potential for Reducing Disparities
Morris, Alanna A.
Testani, Jeffrey M.
Butler, Javed
[J]. CIRCULATION, 2021, 143 (24) : 2329 - 2331
[42] Qualitative evaluation to Understand barriers and facilitators to prescribing angiotensin receptor-neprilysin inhibitors (ARNi) and sodium-glucose cotransporter inhibitors (SGLT2i) in patients with heart failure with reduced ejection fraction (HFrEF)
Pradhan, Apoorva M.
Lussier, Mia E.
Nguyen, My
Voyce, Stephen J.
Wright, Eric A.
[J]. JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2024, 64 (06)
[43] Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?
Pafili, K.
Papanas, N.
[J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (08) : 693 - 695
[44] Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond
Singh, Jagdeep S. S.
Lang, Chim C.
[J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2015, 11 : 283 - 295
[45] Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
Yang Fan
Meng Ran
Zhu Da-Long
[J]. 慢性疾病与转化医学(英文), 2020, 06 (04) : 239 - 245
[46] Expanding Clinical Use of Sodium-glucose Cotransporter-2 Inhibitors?
Dhawan, Richa
Chaney, Mark A.
[J]. JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2024, 38 (10) : 2135 - 2138
[47] Sodium-glucose cotransporter-2 inhibitors reduce risk of nephrolithiasis
Di Lellis, Maddalena Angela
[J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2024, 149 (12) : 674 - 675
[48] Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections
Sarafidis, Pantelis
Papagianni, Aikaterini
[J]. ANNALS OF INTERNAL MEDICINE, 2019, 171 (12) : 943 - 944
[49] Sodium-glucose cotransporter-2 inhibitors in patients without diabetes
Fryml, Elise
Lanktree, Matthew B.
[J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2023, 195 (17) : E619 - E619
[50] Sodium-glucose cotransporter-2 inhibitors reduce the risk of gout
Pavlicek, Vojtech
[J]. DIABETOLOGE, 2020, 16 (02): : 190 - 191

← 1 2 3 4 5 →